The role of soluble B cell maturation antigen as a biomarker in multiple myeloma

References

• Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364(11):1046–1060.
   PubMed Web of Science ®Google Scholar
• Padala SA, Barsouk A, Barsouk A, et al. Staging, and management of multiple myeloma. Med Sci. 2021;9(1), https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7838784/.
   Google Scholar
• Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538–e548.
   PubMed Web of Science ®Google Scholar
• Soekojo CY, Chung TH, Furqan MS, et al. Genomic characterization of functional high-risk multiple myeloma patients. Blood Cancer J. 2022;12(1):24.
   PubMed Web of Science ®Google Scholar
• Charliński G, Jurczyszyn A. Non-secretory multiple myeloma: diagnosis and management. Adv Clin Exp Med. 2022;31(1):95–100.
   PubMed Web of Science ®Google Scholar
• Laâbi Y, Gras MP, Carbonnel F, et al. A new gene, BCM, on chromosome 16 is fused to the interleukin 2 gene by a t(4;16)(q26;p13) translocation in a malignant T cell lymphoma. EMBO J. 1992;11(11):3897–3904.
   PubMed Web of Science ®Google Scholar
• Laabi Y, Gras MP, Brouet JC, et al. The BCMA gene, preferentially expressed during B lymphoid maturation, is bidirectionally transcribed. Nucleic Acids Res. 1994;22(7):1147–1154.
   PubMed Web of Science ®Google Scholar
• Carpenter RO, Evbuomwan MO, Pittaluga S, et al. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin Cancer Res. 2013;19(8):2048–2060.
   PubMed Web of Science ®Google Scholar
• Reboldi A, Cyster JG. Peyer’s patches: organizing B-cell responses at the intestinal frontier. Immunol Rev. 2016;271(1):230–245.
   PubMed Web of Science ®Google Scholar
• O'Connor BP, Raman VS, Erickson LD, et al. BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med. 2004;199(1):91–98.
   PubMed Web of Science ®Google Scholar
• Benson MJ, Dillon SR, Castigli E, et al. Cutting edge: the dependence of plasma cells and independence of memory B cells on BAFF and APRIL. J Immunol. 2008;180(6):3655–3659.
   PubMed Web of Science ®Google Scholar
• Claudio JO, Masih-Khan E, Tang H, et al. A molecular compendium of genes expressed in multiple myeloma. Blood. 2002;100(6):2175–2186.
   PubMed Web of Science ®Google Scholar
• Shen X, Guo Y, Qi J, et al. Binding of B-cell maturation antigen to B-cell activating factor induces survival of multiple myeloma cells by activating Akt and JNK signaling pathways. Cell Biochem Funct. 2016;34(2):104–110.
   PubMed Web of Science ®Google Scholar
• Moreaux J, Legouffe E, Jourdan E, et al. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood. 2004;103(8):3148–3157.
   PubMed Web of Science ®Google Scholar
• Schuh E, Musumeci A, Thaler FS, et al. Human plasmacytoid dendritic cells display and shed B cell maturation antigen upon TLR engagement. J Immunol. 2017;198(8):3081–3088.
   PubMed Web of Science ®Google Scholar
• Chauhan D, Singh AV, Brahmandam M, et al. Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target. Cancer Cell. 2009;16(4):309–323.
   PubMed Web of Science ®Google Scholar
• Tai YT, Acharya C, An G, et al. APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment. Blood. 2016;127(25):3225–3236.
   PubMed Web of Science ®Google Scholar
• Tai YT, Mayes PA, Acharya C, et al. Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood. 2014;123(20):3128–3138.
   PubMed Web of Science ®Google Scholar
• Shah N, Chari A, Scott E, et al. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Leukemia. 2020;34:985–1005. https://doi.org/10.1038/s41375-020-0734-z
   PubMed Web of Science ®Google Scholar
• Davis J, McGann M, Shockley A, et al. Idecabtagene vicleucel versus ciltacabtagene autoleucel: a Sophie’s choice for patients with relapsed refractory multiple myeloma. Expert Rev Hematol. 2022;15(6):473–475.
   PubMed Web of Science ®Google Scholar
• Sharma P, Kanapuru B, George B, et al. FDA approval summary: idecabtagene vicleucel for relapsed or refractory multiple myeloma. Clin Cancer Res. 2022;28(9):1759–1764.
   PubMed Web of Science ®Google Scholar
• Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021;398(10297):314–324.
   PubMed Web of Science ®Google Scholar
• Munshi NC, Anderson LD Jr., Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705–716.
   PubMed Web of Science ®Google Scholar
• Ni S, Zhuo Z, Pan Y, et al. Recent progress in aptamer discoveries and modifications for therapeutic applications. ACS Appl Mater Interfaces. 2021;13(8):9500–9519.
   PubMed Web of Science ®Google Scholar
• Catuogno S, Di Martino MT, Nuzzo S, et al. An anti-BCMA RNA aptamer for miRNA intracellular delivery. Mol Ther Nucleic Acids. 2019;18:981–990.
   PubMedGoogle Scholar
• Moreaux J, Cremer FW, Reme T, et al. The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature. Blood. 2005;106(3):1021–1030.
   PubMed Web of Science ®Google Scholar
• Abe M, Kido S, Hiasa M, et al. BAFF and APRIL as osteoclast-derived survival factors for myeloma cells: a rationale for TACI-Fc treatment in patients with multiple myeloma. Leukemia. 2006;20(7):1313–1315.
   PubMed Web of Science ®Google Scholar
• Matthes T, Dunand-Sauthier I, Santiago-Raber ML, et al. Production of the plasma-cell survival factor a proliferation-inducing ligand (APRIL) peaks in myeloid precursor cells from human bone marrow. Blood. 2011;118(7):1838–1844.
   PubMed Web of Science ®Google Scholar
• Hendriks J, Planelles L, de Jong-Odding J, et al. Heparan sulfate proteoglycan binding promotes APRIL-induced tumor cell proliferation. Cell Death Differ. 2005;12(6):637–648.
   PubMed Web of Science ®Google Scholar
• Cerutti A. The regulation of IgA class switching. Nat Rev Immunol. 2008;8(6):421–434.
   PubMed Web of Science ®Google Scholar
• Marsters SA, Yan M, Pitti RM, et al. Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI. Curr Biol. 2000;10(13):785–788.
   PubMed Web of Science ®Google Scholar
• Mackay F, Schneider P, Rennert P, et al. BAFF and APRIL: a tutorial on B cell survival. Annu Rev Immunol. 2003;21:231–264.
   PubMed Web of Science ®Google Scholar
• Jourdan M, Cren M, Robert N, et al. IL-6 supports the generation of human long-lived plasma cells in combination with either APRIL or stromal cell-soluble factors. Leukemia. 2014;28(8):1647–1656.
   PubMed Web of Science ®Google Scholar
• Bossen C, Schneider P. BAFF, APRIL and their receptors: structure, function and signaling. Semin Immunol. 2006;18(5):263–275.
   PubMed Web of Science ®Google Scholar
• Haiat S, Billard C, Quiney C, et al. Role of BAFF and APRIL in human B-cell chronic lymphocytic leukaemia. Immunology. 2006;118(3):281–292.
   PubMed Web of Science ®Google Scholar
• Roy P, Sarkar UA, Basak S. The NF-kappaB activating pathways in multiple myeloma. Biomedicines. 2018;6(2):59.
   PubMed Web of Science ®Google Scholar
• Scott O, Roifman CM. NF-kappaB pathway and the goldilocks principle: lessons from human disorders of immunity and inflammation. J Allergy Clin Immunol. 2019;143(5):1688–1701.
   PubMed Web of Science ®Google Scholar
• Vrabel D, Pour L, Sevcikova S. The impact of NF-kappaB signaling on pathogenesis and current treatment strategies in multiple myeloma. Blood Rev. 2019;34:56–66.
   PubMed Web of Science ®Google Scholar
• Hatzoglou A, Roussel J, Bourgeade MF, et al. TNF receptor family member BCMA (B cell maturation) associates with TNF receptor-associated factor (TRAF) 1, TRAF2, and TRAF3 and activates NF-kappa B, elk-1, c-Jun N-terminal kinase, and p38 mitogen-activated protein kinase. J Immunol. 2000;165(3):1322–1330.
   PubMed Web of Science ®Google Scholar
• Laurent SA, Hoffmann FS, Kuhn PH, et al. gamma-Secretase directly sheds the survival receptor BCMA from plasma cells. Nat Commun. 2015;6:7333.
   PubMed Web of Science ®Google Scholar
• Levine SJ. Molecular mechanisms of soluble cytokine receptor generation. J Biol Chem. 2008;283(21):14177–14181.
   PubMed Web of Science ®Google Scholar
• Chen H, Li M, Sanchez E, et al. Gene expression of gamma secretase (GS) complex-related proteins, the enzyme that sheds B-cell maturation antigen (BCMA), among patients with multiple myeloma (MM) and effects of the GS inhibitor LSN424354 on solubilized BCMA in MM and chronic lymphocytic leukemia. Blood. 2016;128(22):5641–5641.
   Web of Science ®Google Scholar
• Łacina P, Butrym A, Frontkiewicz D, et al. Soluble CD147 (BSG) as a prognostic marker in multiple myeloma. Curr Issues Mol Biol. 2022;44(1):350–359.
   PubMed Web of Science ®Google Scholar
• Lonial S, Grosicki S, Hus M, et al. Synergistic effects of low-dose belantamab mafodotin in combination with a gamma-secretase inhibitor (nirogacestat) in patients with relapsed/refractory multiple myeloma (RRMM): DREAMM-5 study. J Clin Oncol. 2022;40(16_suppl):8019.
   Web of Science ®Google Scholar
• Pont MJ, Hill T, Cole GO, et al. gamma-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma. Blood. 2019;134(19):1585–1597.
   PubMed Web of Science ®Google Scholar
• Lee L, Bounds D, Paterson J, et al. Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma. Br J Haematol. 2016;174(6):911–922.
   PubMed Web of Science ®Google Scholar
• Sanchez E, Li M, Kitto A, et al. Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival. Br J Haematol. 2012;158(6):727–738.
   PubMed Web of Science ®Google Scholar
• Ghermezi M, Li M, Vardanyan S, et al. Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients. Haematologica. 2017;102(4):785–795.
   PubMed Web of Science ®Google Scholar
• Visram A, Soof C, Rajkumar SV, et al. Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients. Blood Cancer J. 2021;11(6):120.
   PubMed Web of Science ®Google Scholar
• Bujarski S, Udd K, Soof C, et al. Baseline and changes in serum B-cell maturation antigen levels rapidly indicate changes in clinical status among patients with relapsed/refractory multiple myeloma starting new therapy. Target Oncol. 2021;16(4):503–515.
   PubMed Web of Science ®Google Scholar
• Bujarski S, Sutanto C, Spektor TM, et al. Use of serum B-cell maturation antigen levels to predict outcomes for myeloma patients treated with ruxolitinib, lenalidomide and methylprednisolone. Hematol Oncol. 2022;40(2):243–248.
   PubMed Web of Science ®Google Scholar
• Trudel S, Lendvai N, Popat R, et al. Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial. Lancet Oncol. 2018;19(12):1641–1653.
   PubMed Web of Science ®Google Scholar
• Chen H, Li M, Xu N, et al. Serum B-cell maturation antigen (BCMA) reduces binding of anti-BCMA antibody to multiple myeloma cells. Leuk Res. 2019;81:62–66.
   PubMed Web of Science ®Google Scholar
• Jew S, Bujarski S, Soof C, et al. Estimating a normal reference range for serum B-cell maturation antigen levels for multiple myeloma patients. Br J Haematol. 2021;192(6):1064–1067.
   PubMed Web of Science ®Google Scholar
• Jew S, Chang T, Bujarski S, et al. Normalization of serum B-cell maturation antigen levels predicts overall survival among multiple myeloma patients starting treatment. Br J Haematol. 2021;192(2):272–280.
   PubMed Web of Science ®Google Scholar
• Udd KA, Soof CM, Etessami S, et al. Changes in serum B-Cell maturation antigen levels are a rapid and reliable indicator of treatment efficacy for patients with multiple myeloma. Clin Lymphoma Myeloma Leukemia. 2017;17.
   Web of Science ®Google Scholar
• Dispenzieri A, Soof CM, Rajkumar SV, et al. Serum BCMA levels to predict outcomes for patients with MGUS and smoldering multiple myeloma (SMM). J Clin Oncol. 2019;37(15_suppl):8020–8020.
   Google Scholar
• Vardanyan S, Meid K, Udd KA, et al. Serum levels of B-cell maturation antigen are elevated in waldenström’s macroglobulinemia patients and correlate with disease status and conventional M-Protein and IgM levels. Blood. 2015;126(23):1778–1778.
   Web of Science ®Google Scholar
• Udd KA, Bujarski S, Wirtschafter E, et al. Plasma B-cell maturation antigen levels are elevated and correlate with disease activity in patients with chronic lymphocytic leukemia. Target Oncol. 2019;14(5):551–561.
   PubMed Web of Science ®Google Scholar
• Salazar-Camarena DC, Palafox-Sanchez CA, Cruz A, et al. Analysis of the receptor BCMA as a biomarker in systemic lupus erythematosus patients. Sci Rep. 2020;10(1):6236.
   PubMed Web of Science ®Google Scholar
• Bansal R, Rakshit S, Kumar S. Extramedullary disease in multiple myeloma. Blood Cancer J. 2021;11(9):161.
   PubMed Web of Science ®Google Scholar
• Jung SH, Kim K, Kim JS, et al. A prognostic scoring system for patients with multiple myeloma classified as stage II with the revised international staging system. Br J Haematol. 2018;181(5):707–710.
   PubMed Web of Science ®Google Scholar
• Berenson A, Vardanyan S, David M, et al. Improved clinical outcomes for multiple myeloma patients treated at a single specialty clinic. Ann Hematol. 2017;96(3):441–448.
   PubMed Web of Science ®Google Scholar
• Kunacheewa C, Manasanch EE. The benefits of early intervention using lenalidomide for high-risk smoldering multiple myeloma: emerging data and its promising clinical impact. Expert Rev Hematol. 2021;14(12):1059–1069.
   PubMed Web of Science ®Google Scholar
• Kunacheewa C, Manasanch EE. High-risk smoldering myeloma versus early detection of multiple myeloma: current models, goals of therapy, and clinical implications. Best Pract Res Clin Haematol. 2020;33(1):101152.
   PubMed Web of Science ®Google Scholar
• Gertz M. Smoldering multiple myeloma: reviewing the rationale for intervention. Leuk Lymphoma. 2022;9:1–8.
   Google Scholar
• Bhole MV, Sadler R, Ramasamy K. Serum-free light-chain assay: clinical utility and limitations. Ann Clin Biochem. 2014;51(Pt 5):528–542.
   PubMed Web of Science ®Google Scholar
• Hansen CT, Pedersen PT, Nielsen LC, et al. Evaluation of the serum free light chain (sFLC) analysis in prediction of response in symptomatic multiple myeloma patients: rapid profound reduction in involved FLC predicts achievement of VGPR. Eur J Haematol. 2014;93(5):407–413.
   PubMed Web of Science ®Google Scholar
• Dejoie T, Fouquet G, Hulin C, et al. Light chain escape in multiple myeloma. Blood. 2018;132(Supplement 1):1881.
   Google Scholar
• Waldmann TA, Strober W. Metabolism of immunoglobulins. Prog Allergy. 1969;13:1–110.
   PubMedGoogle Scholar
• Sanchez E, Gillespie A, Tang G, et al. Soluble B-cell maturation antigen mediates tumor-induced immune deficiency in multiple myeloma. Clin Cancer Res. 2016;22(13):3383–3397.
   PubMed Web of Science ®Google Scholar
• Samur MK, Fulciniti M, Aktas Samur A, et al. Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma. Nat Commun. 2021;12(1):868–868.
   PubMed Web of Science ®Google Scholar
• Rennert P, Schneider P, Cachero TG, et al. A soluble form of B cell maturation antigen, a receptor for the tumor necrosis factor family member APRIL, inhibits tumor cell growth. J Exp Med. 2000;192(11):1677–1684.
   PubMed Web of Science ®Google Scholar
• Meermeier EW, Welsh SJ, Sharik ME, et al. Tumor burden limits bispecific antibody efficacy through T cell exhaustion averted by concurrent cytotoxic therapy. Blood Cancer Discov. 2021;2(4):354–369.
   PubMedGoogle Scholar
• Raje N, Berdeja J, Lin Y, et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019;380(18):1726–1737.
   PubMed Web of Science ®Google Scholar
• Cowan AJ, Pont M, Sather BD, et al. Efficacy and safety of fully human BCMA CAR T cells in combination with a gamma secretase inhibitor to increase BCMA surface expression in patients with relapsed or refractory multiple myeloma. Blood. 2019;134(Supplement_1):204–204.
   Google Scholar
• Pratt G, Mead GP, Godfrey KR, et al. The tumor kinetics of multiple myeloma following autologous stem cell transplantation as assessed by measuring serum-free light chains. Leuk Lymphoma. 2006;47(1):21–28.
   PubMed Web of Science ®Google Scholar
• Jagannath S. Value of serum free light chain testing for the diagnosis and monitoring of monoclonal gammopathies in hematology. Clin Lymphoma Myeloma. 2007;7(8):518–523.
   PubMedGoogle Scholar
• Cho SF, Anderson KC, Tai YT. Targeting B cell maturation antigen (BCMA) in multiple myeloma: Potential uses of BCMA-Based immunotherapy. Front Immunol. 2018;9:1821.
   PubMed Web of Science ®Google Scholar